Results 81 to 90 of about 46,150 (319)

Spironolactone and diabetic ketoacidosis [PDF]

Postgraduate Medical Journal, 1981
Summary The authors describe a diabetic patient on spironolactone who, following a minor surgical procedure, developed ketoacidosis and life-threatening hyperkalaemia.
A. Lever, A. G. Jariwalla, C. R. Jones, R. Hall   +3 more
openaire   +3 more sources

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

BMC Nephrology, 2020
Background Limited evidence has indicated that addition of a steroidal mineralocorticoid receptor antagonist (MRA) to the standard of care reduces proteinuria in patients with diabetic kidney disease (DKD); however, there are limited data regarding real ...
Michael Blankenburg, Csaba P. Kovesdy, Anne-Kathrin Fett, Raymond G. Griner, Alain Gay   +4 more
doaj   +1 more source

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm [PDF]

, 2016
Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of ...
Abozguia, AIRE Study Group, Alexander, Alexander, Alexander, Alexander, Ashrafian, Bailey, Bailey, Basu, Beadle, Braunwald, Brown, Burgoyne, Chaitman, Chatterjee, Chung, CIBIS-II Study Group, Cleland, Clerc, Cohn, Cohn, Cohn, CONSENSUS Trial Study Group, Conway, Cook, Dai, Digitalis Investigation Group, Doenst, Dzau, Dzau, Faris, Flather, Follath, Foster, Fox, Fox, Fragasso, Furberg, Gheorghiade, Gladwin, Goffart, Granger, Greenberg, Guazzi, Guazzi, Heymans, Hobbs, Holubarsch, Horowitz, Horowitz, Kantor, Kapil, Kato, Kennedy, Kennedy, Kostis, Larsen, Lee, Lopaschuk, Luiken, Lundberg, Maher, Maier, Mancini, Mann, Mann, Massie, Mccormack, Mcdowell, Mcmurray, Mcmurray, Merit-Hf Study Group, Munzel, Munzel, Neglia, Neubauer, Ormerod, Packer, Packer, Paul, Pawson, Pfeffer, Pfeffer, Pitt, Pitt, Rathore, Rauchhaus, Redfield, Rona, Sack, Sarraf, Schmidt-Schweda, Schrauwen, Schwarz, Shah, Shah, Siddiqi, Singh, SOLVD Investigators, Stanley, Swedberg, Szwed, Taylor, Teerlink, Tilemann, Torre-Amione, Totzeck, Turcani, Unger, Van Der Vusse, Van Faassen, Vardeny, Webb, Yin, Yusuf, Zamani, Zannad, Zannad, Zhang   +119 more
core   +1 more source

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

ESC Heart Failure, EarlyView.
Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction.
Gonzalo Luis Alonso Salinas, Amaia Martínez León, Diego Aguiar Cano, Alberto Esteban‐Fernández, José María Viéitez Flórez, Susana del Prado Díaz, Juan Górriz‐Magaña, Gregorio de Lara Delgado, Rafael González‐Manzanares, Pedro Caravaca‐Pérez, Francisco J. Pastor‐Pérez, Sandra Valdivieso‐Moré, Juan Quiles, Inés Ponz, Vanessa Escolar, Edison Omar Boada Lincango, Néstor Báez‐Ferrer, Gonzalo Gallego, Luis Almenar, Luis Gutiérrez de la Varga, Pau Codina, Alejandro Recio Mayoral, Aleix Fort, María Jesús Pinilla Lozano, David González‐Calle, Inés Gómez‐Otero, Cristina Salazar Mosteiro, Marta Cobo, Jesús Piqueras‐Flores, Clara Bonanad, Ana Huerta, Maria Ferré Vallverdú, Pablo Díez‐Villanueva   +32 more
wiley   +1 more source

Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program

International Journal of Women's Dermatology, 2019
Purpose: The necessity of serum potassium monitoring for healthy women who are prescribed spironolactone for acne has been debated. The aim of this study was to compare the incidence of hyperkalemia in women 18 to 45 years of age to that in women 46 to ...
Rebecca M. Thiede, Supriya Rastogi, Beatrice Nardone, Lauren M. Sadowsky, Stephanie M. Rangel, Dennis P. West, Bethanee J. Schlosser   +6 more
doaj  

An overview of the management of Congestive Heart Failure in Malta [PDF]

, 2004
Background: In July 2003 the National Institute of Clinical Excellence (NICE) issued guidelines on the management of congestive heart failure. We set out to assess the management of congestive heart failure in St. Luke's Hospital (SLH), Malta.
Camilleri, Nicola, Sammut, David, Schembri, Stuart   +2 more
core  

Endocrinology of Transgender Medicine [PDF]

, 2018
Gender-affirming treatment of transgender people requires a multidisciplinary approach in which endocrinologists play a crucial role. The aim of this paper is to review recent data on hormonal treatment of this population and its effect on physical ...
Arcelus, Jon, Gooren, Louis, Klink, Daniel, T'Sjoen, Guy, Tangpricha, Vin   +4 more
core   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

ESC Heart Failure, EarlyView.
Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various disease conditions.
Jiao Wang, Meijuan Zheng, Yuchun Yang, Lei Zhang, Muhuyati Wulasihan   +4 more
wiley   +1 more source